FDA accepts Roche's New Drug Application for fenebrutinib
The U.S. FDA accepted Roche's New Drug Application under priority review for fenebrutinib to treat relapsing and primary progressive multiple sclerosis.
The U.S. FDA accepted Roche's New Drug Application under priority review for fenebrutinib to treat relapsing and primary progressive multiple sclerosis.